Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine. Nora's lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF) procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100's mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/17/14 | $18,000,000 | Series B |
Novo A/S Prospect Venture Partners Rho Ventures Vivo Ventures | undisclosed |
